SonaCare Medical, LLC (SonaCare Medical), a privately held venture-backed healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and significantly improve quality of life. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) surgical ablation systems. Our product line currently includes: Sonatherm® laparoscopic HIFU surgical ablation system, 510(k) cleared in the United States for soft tissue ablation (K070779); Sonablate®450, approved for investigational use within the U.S. and is being studied in a clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; and Sonablate® 500 (CE Mark) approved for the treatment of prostate cancer in more than 30 countries outside the U.S.
Today, more than 130 Sonablate 500 systems are installed in more than 30 countries. Over 12,000 prostate cancer patients have been treated with Sonablate 500, which are documented in several peer-reviewed publications spanning 13 years of clinical outcomes. Additionally, the International HIFU division operates a unique service coordination program for physicians and patients who receive HIFU treatments at International Treatment Centers.
With the changing healthcare environment, SonaCare Medical is expanding HIFU into new applications. Oncologic therapies are shifting away from surgery and radiation towards more focused, less invasive treatments that may provide equivalent cancer control but with fewer side effects. In response, SonaCare Medical is developing a next generation of innovative HIFU technologies treating a variety of clinical urologic applications. – less